// App-Quantinova.ai

461 : Additions to Methotrexate with Conventional and Biologic Dmards in Rheumatoid Arthritis: Are There Differences in Subsequent Time to Treatment Failure?

Researchers

Presenter

  • Sasha Bernatsky

Principal Investigators

  • Orit Schieir

  • Cristiano S. Moura

  • Marie-France Valois

  • Susan J. Bartlett

  • Carol A Hitchon

  • Janet E. Pope

  • Gilles Boire

  • Boulos Haraoui

  • Edward C. Keystone

  • Diane Tin

  • Carter Thorne

Medical Centers

  • Vivian P. Bykerk

  • Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada

  • Montreal University, Montreal, QC, Canada

  • Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada

  • Montreal University, Montreal, QC, Canada

  • Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada

  • Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada

  • Department of Medicine, Division of Rheumatology, University of Western Ontario, St. Joseph’s Health Care, London, ON, Canada,

  • Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada

  • Institut de Rhumatologie, Montreal, QC, Canada

  • University of Toronto, Toronto, ON, Canada

  • The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada,

  • University of Toronto, Newmarket, Canada

  • Mount Sinai Hospital, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Methotrexate

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved